
Radiation onc @PennMedicine | Brain tumor research | Alum of @MSK_RadOnc @Harvardmed @Penn
University of Pennsylvania
Joined June 2021
- Tweets78
- Following429
- Followers310
- Likes807
It was great working with @neuromikeperez and team on this analysis showing no significant association between radiation modality (proton vs photon) and clinically significant necrosis among pts with Grade 2/3 IDHm gliomas. Looking forward to detailed dosimetric analyses led by @jsunny99. #SNO2026
I was thrilled to present our work at #SNO2026 in Philadelphia! 🧠 We studied clinically significant radiation necrosis after proton vs photon radiotherapy for grade 2/3 IDH-mutant gliomas. Grateful to @EmilyLebow and our @PennMedicine team. 🧵
5
293
Happy to share our new study in @IJROBP and presented today at @NeuroOnc, led by Dr. Lauren Linkowski, @MessingIan, Melanie Berger.
Glioblastoma remains a disease with few effective therapies and often recurs within a year despite multi-modality treatment.
We evaluated hypofractionated proton re-irradiation for patients with recurrent glioblastoma.
🔗 redjournal.org/article/S0360…
Emily Lebow, MD retweeted
🚨👏Congrats to Drs Daphna Gelblum, Christopher Barker, Abe Wu of @MSK_RadOnc @MSKCancerCenter for being awarded #ASTRO26 @ASTRO_org fellows!
Emily Lebow, MD retweeted
👏👏Congrats to @ALLIANCE_org, @PDBrownOnc , Dr. Ayal Aizer & the team for Alliance A071801 Ph III postop single vs frac SRS for brain mets, & the eloquent discussion by @Rrkotecha!!
🌟fractionated-SRS ⬆️ surgical bed control, OS (exploratory), and ⬇️ WBRT.
@ASTRO_org #ASTRO26
Emily Lebow, MD retweeted
Our manuscript, "Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas" published in the @JCO_ASCO
ascopubs.org/doi/10.1200/JCO…
Emily Lebow, MD retweeted
🧵1/3 Kudos to Cole Friedes, Melanie Berger, Lauren Linkowski, @EmilyLebow and colleagues in the Penn Brain Tumor Center for their publication today on clinical, molecular and immunologic determinants of #survival in #WHO-defined #IDH-wt #glioblastoma treated with #radiotherapy - a large real-world cohort study.
@PennRadOnc @PennNSG @PennCancer @PennMedCSO
link.springer.com/article/10…
Emily Lebow, MD retweeted
Always a highlight of @ASTRO_org Meetings, the Awards ceremony🔥 Because we like to celebrate our community🥳
Huge shoutout to classmate, friend, role model, and mentoring force Helen Shih of MGH/MGB👏👏👏 (now she just needs to join #SoMe‼️)
#ASTRO25
@DKirschMDPhD @AmyWisdom8 @EmilyLebow
I was privileged to nominate Dr Helen Shih for the ASTRO Mentorship Award and thrilled to see her honored this year along side Drs Gibbs and Yahalom🌟 She’s been an incredible mentor to me since med school in 2016, shaping my path in rad onc and inspiring me to mentor others
1
5
321
Special thanks to @JHGLab, @LiaHalaszMD , @KylieKangMD, Luke Pike. @RachelJimenezMD, @DrWilliamHwang, @BrandonMahal, @MinaBakhtiar, @AmyWisdom8, @ShervinTabrizi, @theabzlab, @EJVaios, @DanielKimMD, and many others who contributed to the nomination 🙌 @HarvardRadOnc
3
263
Emily Lebow, MD retweeted
Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!!
They will be recognized at #ASTRO25 in San Francisco. @StanfordRadOnc @MassGeneralNews @MSK_RadOnc
ow.ly/A1cB50WlXIa
Emily Lebow, MD retweeted
#ASCO25: @StephenBagleyMD on CAR T cell for glioblastoma: “The treatment changed the trajectory of their disease.” Now in @NatureMedicine and on the @ASCO stage today. Abstract 102. @DrORourke2 spr.ly/6018N7k16
Emily Lebow, MD retweeted
The @NCCN Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient.
This award recognizes her impact on cancer care through neuroimaging and biomarker research on neurotoxicity after CAR T-cell therapy: bit.ly/4iQpoo1.
Emily Lebow, MD retweeted
#CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief.
“There’s a lot of loss that led to this research,” Drew’s dad said. “I hope those families know that this success is because of them.”
med.stanford.edu/news/all-ne…
Thanks, @HenningWillers! Great to present promising options for pts with locally advanced #lungcancer who are ineligible for chemoRT. @MSKCancerCenter @MSK_RadOnc
1/2
Promising outcomes of combining #radiotherapy and durvalumab without chemo in LA-NSCLC.
PFS associated with PD-L1.
Wonder if there is a path for personalized therapy where chemo can be dropped in high PDL1?
#ASTRO24
5
735
Emily Lebow, MD retweeted
🧠☢️⚡️New in @JAMAOnc from @MSKCancerCenter #radonc grad Dr @EmilyLebow w/ Dr @yaoyu_md: Antibody-drug conjugates given concurrently with Stereotactic #radiotherapy #SRS were associated with ⬆️risk of symptomatic #radiation necrosis.
More details here: jamanetwork.com/journals/jam…
Emily Lebow, MD retweeted
🫁☢️New in @jitcancer from @MSKCancerCenter #radonc and @DanaFarber: This analysis of outcomes to #chemoradiation & #durvalumab in stage III non-small cell #lungcancer #NSCLC suggests that tumor aneuploidy is a promising predictive biomarker. #lcsm
➡️jitc.bmj.com/content/11/11/e…
Emily Lebow, MD retweeted
Just out in @JAMAOnc - important data on risk factors for #brainmet necrosis with concurrent ADC + SRS: understanding sequencing essential as CNS outcome data emerge @MSK_RadOnc @MSK_DeptOfMed @MSKNeurosurgery @EmilyLebow @yaoyu_md @Dr_Luke_Pike @Dr_N_Moss
In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT. ja.ma/498qFCq
Emily Lebow, MD retweeted
Happy to share our work on SRS with concurrent ADCs, now out @JAMAOnc! In this study, led by @EmilyLebow, we investigated the risk of symptomatic radiation necrosis for pts receiving SRS and brain metastases. ADCs included T-DXd, T-DM1, and SG. (1/n)
jamanetwork.com/journals/jam…




































